The Bile Duct Cancer Treatment Market is all set to be in the driver’s seat shortly. Technology adoption once looked upon as a costly endeavor, is slated to witness a drastic transformation in the form of granular applications. Technologies like DevOps and AIOps are constructively disrupting the healthcare IT sector and are expected to create wonders in this regard in the upcoming period.

The Bile Duct Cancer Treatment Market Share is expected to be worth US$ 312 Million at a CAGR of 8% from 2025. With remote patient monitoring being the epicenter of healthcare, wearable devices are there to rule the roost. With 25% of healthcare centers making use of mobile applications, it is impossible to imagine the healthcare vertical without remote connectivity shortly.

Cholangiocarcinoma, also known as bile duct cancer, is spreading widely in Southeast Asia, particularly in the Northeast region of Thailand. High consumption of raw fish in the Asia-Pacific (APAC) region is driving the incidence of liver fluke infections, thereby stimulating the occurrence of bile duct cancer.

Increased industrialization is also attributing to the growth in the APAC bile duct cancer treatment market style=”font-weight: 400;”> as exposure to harmful printing chemicals is high among industrial workers in countries such as China, Japan and India.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/10094

Company Profiles

• Pfizer, Inc.
• F. Hoffman-La Roche AG
• Bristol-Myers Squibb Company
• Teva Pharmaceuticals Industries Ltd.
• Eli Lilly and Company
• Novartis AG
• Sanofi
• Fresenius Kabi AG
• Mylan N.V.
• Kyowa Hakko Kirin Co Ltd.
• Intercept Pharmaceuticals, Inc.
• Accord Healthcare Inc.
• Delcath Systems Inc.
• Celgene Corporation
• Johnson & Johnson

Get A Customized Scope To Match Your Need Ask An Expert – sales@persistencemarketresearch.com

Persistence Market Research’s new study on the global bile duct cancer treatment market reveals that by the end of 2025, APAC region will procure a global revenue share of over 45%.

In 2017, the global market for bile duct cancer treatments is anticipated to bring in revenues worth a little over US$ 168 Mn. Apart from rising incidence of bile duct cancer across the APAC and Middle East & Africa region, increasing healthcare spending is also expected to drive the demand for bile duct cancer treatments.

Towards the end of 2025, the global bile duct cancer treatment market is projected to soar at a robust CAGR of 8%, raking in revenues worth US$ 312.3 Mn.

Bile Duct Cancer Treatment – Key Challenges

The study has observed following factors as key hurdles hindering the overall expansion of global Cholangiocarcinoma treatment market:

• high costs of cancer treatment in the US
• lack of awareness on causes of Cholangiocarcinoma in developing regions
• regulatory agencies rebuffing approval of expensive drugs
• unavailability of effective cancer care in APAC region
• poor diagnosis rate and absence of clinical data

The study also reveals that ongoing trials for development of drugs on bile duct cancer treatment are creating newer pathways for improving the efficiency of treatment. Companies are exploring the clinical benefits of fusing new chemical entities in existing drugs on treatment of bile duct cancer.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/10094

The key players in global bile duct cancer treatment market are also seeking regulatory approval of combination therapies for treatment of Cholangiocarcinoma.

Key Excerpts from the Study

Treatment of bile duct cancer is presently achieved through combination therapies associated with chemotherapy. The study anticipates that by the end of forecast period, close to 70% of global bile duct cancer treatment revenues will be accounted by the Gemicitabine Combination Therapy.

In 2017 and beyond, more than 85% of global market value will be attributed by extrahepatic Cholangiocarcinoma as a disease indicator.

The study also observes hospital pharmacies as largest distribution channel for bile duct cancer drugs, revenues from which are expected to reach nearly US$ 250 Mn by 2025-end.

The global market for Cholangiocarcinoma treatment is also witnessing dominance from external beam radiation therapy as these services are pegged to procure more than half of market’s value through 2025.

About us: Persistence Market Research

Contact us:

Persistence Market Research          
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com